• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    INmune Bio Inc. - Common stock (NQ:INMB)

    1.340 +0.010 (+0.75%)
    Streaming Delayed Price Updated: 9:38 AM EDT, Mar 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about INmune Bio Inc. - Common stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
    Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
    From INmune Bio, Inc.
    Via GlobeNewswire
    INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? ↗
    Via Stocktwits
    News headline image
    INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For October 30, 2025 ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
     
    Via Benzinga
    News headline image
    INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INMUNE BIO INC (NASDAQ:INMB) Reports Narrower-Than-Expected Q3 2025 Loss ↗
    INmune Bio (INMB) reported a narrower-than-expected Q3 2025 loss, sparking a positive after-hours market reaction for the clinical-stage biotech firm. 
    Via Chartmill
    News headline image
    INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio (INMB) Q2 Loss Widens 110% ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    What's going on in today's pre-market session ↗
    As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge? ↗
    Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday. 
    Via Benzinga
    News headline image
    INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday ↗
    Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. 
    Via Benzinga
    News headline image
    Which stocks have an unusual volume on Thursday? ↗
    The trading volume of these stocks is deviating from the norm in today's session. 
    Via Chartmill
    News headline image
    This Textron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
     
    Via Benzinga
    News headline image
    INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From INmune Bio, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.